Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer

Abstract Muscle invasive bladder cancers (BCs) can be divided into 2 major subgroups-basal/squamous (BASQ) tumors and luminal tumors. Since Pparg has low or undetectable expression in BASQ tumors, we tested the effects of rosiglitazone, Pparg agonist, in a mouse model of BASQ BC. We find that rosigl...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Sakina A. Plumber, Tiffany Tate, Hikmat Al-Ahmadie, Xiao Chen, Woonyoung Choi, Merve Basar, Chao Lu, Aaron Viny, Ekatherina Batourina, Jiaqi Li, Kristjan Gretarsson, Besmira Alija, Andrei Molotkov, Gregory Wiessner, Byron Hing Lung Lee, James McKiernan, David J. McConkey, Colin Dinney, Bogdan Czerniak, Cathy Lee Mendelsohn
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2024-08-01
Edice:	Nature Communications
On-line přístup:	https://doi.org/10.1038/s41467-024-50678-2
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!